Analyst Price Targets — CUE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 15, 2024 1:59 pm | Maury Raycroft | Jefferies | $4.00 | $1.29 | StreetInsider | Cue Biopharma (CUE) PT Lowered to $4 at Jefferies |
| July 26, 2024 6:14 am | Reni Benjamin | JMP Securities | $2.00 | $0.70 | TheFly | Cue Biopharma price target lowered to $2 from $15 at JMP Securities |
| March 13, 2024 2:52 am | Maury Raycroft | Jefferies | $6.00 | $2.15 | StreetInsider | Jefferies Starts Cue Biopharma (CUE) at Buy, 'Following Nature's "Cues" W/ Targeted IL-2 Therapy' |
| November 20, 2022 6:23 pm | Edward Tenthoff | Piper Sandler | $7.00 | $3.22 | TheFly | Cue Biopharma initiated with an Overweight at Piper Sandler |
Latest News for CUE
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of the company's shareholders. The investigation seeks to determine whether Cue Biopharma's directors breached their fiduciary duties in connection with recent corporate actions.
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CUE.
U.S. House Trading
No House trades found for CUE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.